Published in Arch Dermatol Res on January 01, 1995
Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol (1988) 16.82
Oncogenes and signal transduction. Cell (1991) 14.84
The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature (1988) 14.43
Growth factor receptor tyrosine kinases. Annu Rev Biochem (1988) 8.67
A 38,000-dalton membrane protein (p38) present in synaptic vesicles. Proc Natl Acad Sci U S A (1985) 4.35
Regulation of transmembrane signaling by receptor phosphorylation. Cell (1987) 3.74
Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem (1989) 3.02
Overexpression of transforming growth factor alpha in psoriatic epidermis. Science (1989) 2.63
Tyrosine kinase activation through the extracellular domains of cytokine receptors. Nature (1993) 1.85
Cyclosporin A suppresses ICAM-1 expression by papillary endothelium in healing psoriatic plaques. J Invest Dermatol (1991) 1.60
Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J Invest Dermatol (1990) 1.45
Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol (1990) 1.43
FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. Cell Immunol (1991) 1.12
In vitro tyrosine phosphorylation of PLC-gamma 1 and PLC-gamma 2 by src-family protein tyrosine kinases. Biochem Biophys Res Commun (1993) 1.07
FK-506 enters the clinic. Immunol Today (1990) 1.03
RO 31-8220 and RO 31-7549 show improved selectivity for protein kinase C over staurosporine in macrophages. Biochem Biophys Res Commun (1991) 1.00
Increased dermal expression of platelet-derived growth factor receptors in growth-activated skin wounds and psoriasis. J Invest Dermatol (1991) 0.95
Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol (1992) 0.95
Protooncogene expression in normal and psoriatic skin. J Invest Dermatol (1990) 0.93
Protein tyrosine kinase and protein phosphotyrosine phosphatase in normal and psoriatic skin. Biochim Biophys Acta (1984) 0.93
Cyclosporin A and FK506 mediate differential effects on T cell activation in vivo. J Immunol (1992) 0.91
Additive and synergistic antiproliferative effects of cyclosporin A and gamma interferon on cultured human keratinocytes. Am J Pathol (1988) 0.89
Cyclosporine in psoriasis treatment. Inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor alpha/epidermal growth factor receptor pathways. Arch Dermatol (1991) 0.86
Cyclosporin A inhibits protein kinase C activity: a contributing mechanism in the development of nephrotoxicity? Biochem Biophys Res Commun (1989) 0.86
Signal transduction in the control of cell growth and development. Trends Genet (1992) 0.85
Inhibition of epidermal growth factor receptor tyrosine kinase activity in A431 human epidermoid cells following psoralen/ultraviolet light treatment. Mol Pharmacol (1989) 0.83
Levels of cyclosporin in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum free versus serum containing media. J Invest Dermatol (1988) 0.82
Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506, and rapamycin. J Invest Dermatol (1994) 0.81
Dithranol mediates pro-oxidative inhibition of polymorphonuclear leukocyte migration and lymphocyte proliferation. Br J Dermatol (1987) 0.80
Keratin gene expression during the resolution of psoriatic plaques: effect of dithranol, PUVA, etretinate and hydroxyurea regimens. Br J Dermatol (1989) 0.80
Topical cyclosporine A inhibits the phorbol ester induced hyperplastic inflammatory response but not protein kinase C activation in mouse epidermis. J Invest Dermatol (1989) 0.79
Gene expression of protein kinase C subtypes in normal and psoriatic epidermis. Arch Dermatol Res (1992) 0.78
Dithranol modulates the leukotriene B4-induced intraepidermal accumulation of polymorphonuclear leukocytes. J Invest Dermatol (1989) 0.78
Influence of FK 506 on T lymphocytes, Langerhans' cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study. Transplant Proc (1991) 0.78
Tyrosine-specific protein phosphorylation in response to anti-CD3 antibody is diminished in old mice. J Gerontol (1992) 0.78
Intralesional injection of cyclosporin in psoriasis. Lancet (1988) 0.77
Direct cytopathic effects of cyclosporine A on rapidly proliferating cultured keratinocytes and dermal fibroblasts. Transplant Proc (1988) 0.77
FKBP-12 is not an inhibitor of protein kinase C. Immunol Invest (1992) 0.77
Anthralin decreases keratinocyte TGF-alpha expression and EGF-receptor binding in vitro. J Invest Dermatol (1992) 0.76
Down-regulation of epidermal growth factor receptors by dithranol. Acta Derm Venereol (1993) 0.76
Effects of cyclosporin A on induced HIT cell alkalinization. Life Sci (1992) 0.76
Non-receptor protein tyrosine kinases of normal tissues. Int J Biochem (1990) 0.76
rab3 is a small GTP-binding protein exclusively localized to synaptic vesicles. Proc Natl Acad Sci U S A (1990) 3.13
Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst (1996) 2.28
Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med (1995) 2.11
Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol (2000) 1.76
Low urinary cortisol excretion in patients with posttraumatic stress disorder. J Nerv Ment Dis (1990) 1.63
Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans. J Mol Biol (1996) 1.41
Fatal hepatic failure with liposomal doxorubicin. Lancet (1993) 1.41
[Contact eczema in housewives. Update from 1986 with reference to results of epicutaneous tests in 2,633 patients]. Hautarzt (1998) 1.39
Traditional tattooing of the gingiva: an Eritrean folk medicine practice. Arch Dermatol (1988) 1.38
Langerhans cells and interdigitating reticulum cells in the thymus-dependent region in human dermatopathic lymphadenitis. Virchows Arch B Cell Pathol (1977) 1.27
P29: a novel tyrosine-phosphorylated membrane protein present in small clear vesicles of neurons and endocrine cells. J Cell Biol (1990) 1.18
Genetic heterogeneity of the ichthyosis, hypogonadism, mental retardation, and epilepsy syndrome. Clinical and biochemical investigations on two patients with Rud syndrome and review of the literature. Eur J Pediatr (1983) 1.06
The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol (1998) 1.04
A family study of atopic dermatitis. Clinical and genetic characteristics of 188 patients and 2,151 family members. Arch Dermatol Res (1990) 1.01
Decline of infectious skin manifestations in the era of highly active antiretroviral therapy. AIDS (2000) 1.00
[Bacterial colonization of chronic wounds. Studies on outpatients in a university dermatology clinic with special consideration of ORSA]. Hautarzt (2004) 0.99
Nonoperative treatment of four esophageal perforations with hemostatic clips. Dis Esophagus (2007) 0.99
T-cell specific microenvironment in mycosis fungoides. Arch Dermatol Res (1976) 0.98
Transanal endoscopic tube decompression of acute colonic obstruction: experience with 51 cases. Surg Endosc (2008) 0.98
Genomic sequences of human protamines whose genes, PRM1 and PRM2, are clustered. Genomics (1990) 0.97
Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group. Br J Cancer (1996) 0.96
[The role of oxidative stress in the pathogenesis and therapy of chronic wounds]. Hautarzt (2002) 0.95
Mycosis fungoides: model for T-lymphocyte homing to the skin? Br J Dermatol (1976) 0.94
Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet (2000) 0.92
Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide. J Immunol (1998) 0.91
Topical immunomodulators--progress towards treating inflammation, infection, and cancer. Lancet Infect Dis (2001) 0.90
Evaluation of metal allergies in patients with coronary stents. Contact Dermatitis (2002) 0.89
Melanoma erysipeloides: successful treatment by chemoimmunotherapy. Br J Dermatol (2000) 0.88
Acquired immune deficiency syndrome-related hyperkeratotic Kaposi's sarcoma with severe lymphoedema: report of five cases. Br J Dermatol (2000) 0.88
Successful treatment of a leg ulcer occurring in a rheumatoid arthritis patient under leflunomide therapy. J Eur Acad Dermatol Venereol (2005) 0.87
Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS (1998) 0.86
Downregulation of tapasin expression in progressive human malignant melanoma. Arch Dermatol Res (2003) 0.86
Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res (1986) 0.85
Ethanol enhances the IFN-gamma, TGF-alpha and IL-6 secretion in psoriatic co-cultures. Br J Dermatol (1996) 0.85
Generation of biologically active anti-Cryptococcus neoformans IgG, IgE and IgA isotype switch variant antibodies by acridine orange mutagenesis. Clin Exp Immunol (1996) 0.85
[Bureau-Barrière syndrome of the hand. A case report on an unusual localization]. Hautarzt (2004) 0.84
Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. Br J Nutr (1996) 0.84
Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associated with spontaneous regression. Lab Invest (1998) 0.84
Tyrosine phosphorylation in psoriatic T cells is modulated by drugs that induce or improve psoriasis. Dermatology (1995) 0.84
Ras gene mutations: a rare event in nonmetastatic primary malignant melanoma. J Invest Dermatol (1995) 0.83
[pH values in chronic wounds. Evaluation during modern wound therapy]. Hautarzt (2003) 0.83
Expression of stromelysin 3 in the stromal elements of human basal cell carcinoma. Diagn Mol Pathol (1992) 0.83
Liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Lancet (1993) 0.83
Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin. Eur J Cancer (2001) 0.83
Homozygous deletion of the p16INK4a and the p15INK4b tumour suppressor genes in a subset of human sporadic cutaneous malignant melanoma. Br J Dermatol (1998) 0.83
[Superficial spreading melanoma. Paget's melanoma]. Dtsch Med Wochenschr (1973) 0.82
Expression cloning of the cDNA encoding a melanoma-associated Ag recognized by mAb HMB-45. Identification as melanocyte-specific Pmel 17 cDNA. Lab Invest (1995) 0.82
Calgranulin C is overexpressed in lesional psoriasis. J Invest Dermatol (2000) 0.81
Clinical results of irradiation combined with local hyperthermia. Cancer (1983) 0.81
[Assessment of value and risks of external treatment with clobetasol-17-propionate (Dermovate)]. Ned Tijdschr Geneeskd (1978) 0.81
Conservation in evolution for a small monomeric phenylalanyl-tRNA synthetase of the tRNA(Phe) recognition nucleotides and initial aminoacylation site. Biochemistry (1996) 0.81
Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo. J Invest Dermatol (2000) 0.81
Contact allergy in patients with periorbital eczema: an analysis of allergens. Data recorded by the Information Network of the Departments of Dermatology. Dermatology (1997) 0.80
Successful treatment of stasis dermatitis with topical tacrolimus. Vasa (2004) 0.80
[Palmoplantar purpura in Duhring's herpetiform dermatitis]. Hautarzt (1989) 0.80
[Contact allergies in patients with eczema of the external ear canal. Results of the Information Network of Dermatological Clinics and the German Contact Allergy Group]. Hautarzt (2000) 0.80
Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy. Cancer Immunol Immunother (1997) 0.80
Lithium and psoriasis: cytokine modulation of cultured lymphocytes and psoriatic keratinocytes by lithium. Arch Dermatol Res (1996) 0.80
Efficient expression of naked plasmid DNA in mucosal epithelium: prospective for the treatment of skin lesions. J Invest Dermatol (1998) 0.80
Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis. Antimicrob Agents Chemother (1993) 0.79
[Cytochemistry of skin infiltrates in myelomonocytic leukemia]. Dtsch Med Wochenschr (1970) 0.79
[HIV-positive patient with multiple ulcers. Lues maligna]. Hautarzt (2003) 0.79
Assessing the levels of immunoglobulins in the saliva of diabetic individuals with periodontitis using checkerboard immunodetection. Oral Dis (2008) 0.79
Using an Apple iPad(™) to assist fibreoptic intubation. Anaesthesia (2013) 0.79
[Acrodermatitis chronica atrophicans with fibrous nodules and monoclonal gammopathy]. Arch Dermatol Forsch (1971) 0.79
Patch test sensitization caused by para-tertiary-butylcatechol. Results of a prospective study with a dilution series. Contact Dermatitis (2001) 0.79
[The histopathology of alopecia areata. With special reference to the duration, location and progession of hair loss]. Arch Dermatol Forsch (1971) 0.78
Occurrence and therapy of secondary acute myeloid leukaemia in two HIV-infected patients. AIDS (1998) 0.78
Acrodermatitis chronica atrophicans and malignant lymphoma. Acta Derm Venereol (1971) 0.78
Reduced growth of beard as the only diagnostic sign in a patient with macroprolactinoma. J Eur Acad Dermatol Venereol (2007) 0.78
Predominant expression of CD44 splice variant v10 in malignant and reactive human skin lymphocytes. J Invest Dermatol (1998) 0.78
Increased activity of factor VIII coagulant associated with venous ulcer in a patient with Klinefelter's syndrome. J Eur Acad Dermatol Venereol (2005) 0.78
Immunomodulatory properties of cimetidine in ARC patients. Clin Immunol Immunopathol (1988) 0.78
[Therapy of pseudolymphomas]. Z Hautkr (1980) 0.78
The lack of protamine 2 (P2) in boar and bull spermatozoa is due to mutations within the P2 gene. Nucleic Acids Res (1990) 0.78
Topical treatment of warts and mollusca with imiquimod. Ann Intern Med (2000) 0.78
Endogenous interferon plasma levels and antipyrine pharmacokinetics in patients with viral infections. Int J Clin Pharmacol Ther Toxicol (1992) 0.78
Granulocyte colony-stimulating factor treatment in AIDS patients. Clin Investig (1992) 0.78
Inhibition of T cell cAMP formation by cyclosporin A and FK506. Naunyn Schmiedebergs Arch Pharmacol (1996) 0.78
Pimecrolimus in an adhesive ointment as a new treatment option for oral lichen planus. Br J Dermatol (2004) 0.77
[Cutaneous manifestation of fungal infection]. Hautarzt (1990) 0.77
HIV-1 RNA levels in cerebrospinal fluid and plasma correlate with AIDS dementia. AIDS (1998) 0.77
[Value of the patient's own test substances in epicutaneous testing]. Hautarzt (1994) 0.77
[Treatment of methicillin-resistant Staphylococcus aureus (MRSA) as part of biosurgical management of a chronic leg ulcer]. Hautarzt (2002) 0.77
Comparative effects of rifampin and/or probenecid on the pharmacokinetics of temazepam and nitrazepam. Int J Clin Pharmacol Ther Toxicol (1990) 0.77
Photochemotherapy of psoriasis. Clinical study of clearing and long-term maintenance treatment. Dermatologica (1981) 0.77